Chiasma's oral ocreotide controls acromegaly in some patients
This article was originally published in Scrip
Executive Summary
Chiasma is raising capital to fund a new drug application (NDA) submission to the US FDA for oral ocreotide in the treatment of acromegaly based on Phase III results that were published on 9 February in the Journal of Clinical Endocrinology and Metabolism (JCEM).
You may also be interested in...
Chiasma Responds To FDA Complete Response With 33% Staff Cut
With a near-term launch of Mycapssa unlikely, Chiasma cuts its commercial staff while it evaluates how to respond to an April complete response letter.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.